Klinikum Chemnitz gGmbH

Futó vizsgálatok

• Toboroz

  Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

  NCT07825064· 2. fázis· Forrás

• Toboroz

  Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

  NCT07789574· 2. fázis· Forrás

• Toboroz

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· 3. fázis· Forrás

• Toboroz

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· 3. fázis· Forrás

• Még nem toboroz

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· 3. fázis· Forrás

• Toboroz

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· 3. fázis· Forrás

• Toboroz

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· 3. fázis· Forrás

• Toboroz

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· 3. fázis· Forrás

• Toboroz

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

  NCT07659782· 2. fázis· Forrás

• Toboroz

  A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  NCT07662213· 3. fázis· Forrás

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· 3. fázis· Forrás

• Még nem toboroz

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· 3. fázis· Forrás

• Toboroz

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  2025-522818-23-00· 3. fázis· Forrás

• Toboroz

  PREFer

  NCT06916416· 2. fázis· Forrás

• Toboroz

  Pembro-FLASH

  NCT06045159· 2. fázis· Forrás

• Toboroz

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· 3. fázis· Forrás

• Toboroz

  Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants

  2025-521762-99-00· 3. fázis· Forrás

• Toboroz

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· 3. fázis· Forrás

• Még nem toboroz

  IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

  2025-521908-22-00· 2/3. fázis· Forrás

• Toboroz

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· 2/3. fázis· Forrás

• Toboroz

  Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.

  2024-512503-39-00· 4. fázis· Forrás

• Toboroz

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Forrás

• Toboroz

  A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· 3. fázis· Forrás

• Toboroz

  PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA

  2024-512922-27-00· 2. fázis· Forrás

• Toboroz

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· 3. fázis· Forrás

• Toboroz

  Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT07197307· 2. fázis· Forrás

• Toboroz

  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

  NCT07026474· 3. fázis· Forrás

• Toboroz

  – IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases

  2024-519929-38-00· 2. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· 2/3. fázis· Forrás

• Toboroz

  Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)

  2024-520050-38-00· 3. fázis· Forrás

• Toboroz

  A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  NCT06911502· 3. fázis· Forrás

• Toboroz

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· 3. fázis· Forrás

• Toboroz

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer

  2024-515884-69-00· 3. fázis· Forrás

• Toboroz

  Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

  NCT06717958· 2. fázis· Forrás

• Toboroz

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· 3. fázis· Forrás

• Toboroz

  Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer

  2024-513122-27-00· 3. fázis· Forrás

• Toboroz

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· 3. fázis· Forrás

• Toboroz

  Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

  NCT06696183· 2. fázis· Forrás

• Toboroz

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· 2. fázis· Forrás

• Toboroz

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· 3. fázis· Forrás

• Toboroz

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· 3. fázis· Forrás

• Még nem toboroz

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· 3. fázis· Forrás

• Toboroz

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· 3. fázis· Forrás

• Toboroz

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· 3. fázis· Forrás

• Toboroz

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· 3. fázis· Forrás

• Toboroz

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· 3. fázis· Forrás

• Toboroz

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· 3. fázis· Forrás

• Toboroz

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  NCT06767514· 3. fázis· Forrás

• Toboroz

  Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

  2022-502352-31-00· 3. fázis· Forrás

Showing 50 of 125.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák15 toboroz
• Akut mieloid leukémia (AML)8 toboroz
• Mielóma multiplex8 toboroz
• Vastagbélrák8 toboroz
• Gyermekkori daganatok6 toboroz
• Akut limfoid leukémia (ALL)4 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)4 toboroz
• Follikuláris limfóma4 toboroz
• Gyomor- és nyelőcsőrák4 toboroz
• Hodgkin-limfóma4 toboroz
• Áttétes emlőrák3 toboroz
• Köpenysejtes limfóma3 toboroz
• Krónikus limfoid leukémia (CLL)3 toboroz
• Krónikus mieloid leukémia (CML)3 toboroz
• Máj- és epeúti rák3 toboroz
• 2-es típusú cukorbetegség2 toboroz
• Fej-nyaki daganatok2 toboroz
• Krónikus vesebetegség2 toboroz
• Méhtestrák2 toboroz
• Mielodiszplasztikus szindróma (MDS)2 toboroz
• Mieloproliferatív neopláziák2 toboroz
• Szarkóma2 toboroz
• Tripla negatív emlőrák2 toboroz
• Zsírmáj (MASLD/MASH)2 toboroz
• Időskori makuladegeneráció1 toboroz
• Petefészekrák1 toboroz
• Prosztatarák1 toboroz
• Stroke (szélütés)1 toboroz
• Szívelégtelenség1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Fut, nem toboroz

  A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT06291220· 1. fázis· Forrás

• Fut, nem toboroz

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· 2. fázis· Forrás

• Fut, nem toboroz

  A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC

  2023-504753-12-00· 3. fázis· Forrás

• Fut, nem toboroz

  Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

  NCT06216158· 3. fázis· Forrás

• Toboroz

  A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

  NCT06285318· Forrás

• Fut, nem toboroz

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· 2. fázis· Forrás

• Toboroz

  Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

  NCT06057402· 4. fázis· Forrás

• Lezárult

  Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)

  2022-502040-13-00· 2. fázis· Forrás

• Leállították

  A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

  NCT05780736· Forrás

• Fut, nem toboroz

  Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy

  NCT05833438· 2. fázis· Forrás

• Lezárult

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  NCT05804032· 3. fázis· Forrás

• Lezárult

  Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)

  NCT05675319· 3. fázis· Forrás

• Lezárult

  EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

  2023-504832-16-00· 2. fázis· Forrás

• Fut, nem toboroz

  A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT05170204· 3. fázis· Forrás

• Lezárult

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

  NCT05403385· 2. fázis· Forrás

• Lezárult

  Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

  NCT05298423· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosis

  2023-509635-89-00· 1/2. fázis· Forrás

• Lezárult

  Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04833114· 3. fázis· Forrás

• Lezárult

  A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

  NCT04620330· 2. fázis· Forrás

• Lezárult

  A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

  NCT04619797· 2/3. fázis· Forrás

• Lezárult

  Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  NCT04191616· 2. fázis· Forrás

• Lezárult

  Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

  NCT04330820· 1/2. fázis· Forrás

• Lezárult

  CIRCULATE

  NCT04089631· 3. fázis· Forrás

• Lezárult

  MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse

  NCT03769532· 2. fázis· Forrás

• Lezárult

  Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

  NCT03740165· 3. fázis· Forrás

• Lezárult

  Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

  NCT03250338· 3. fázis· Forrás

• Lezárult

  Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491· 3. fázis· Forrás

• Lezárult

  A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565· 2. fázis· Forrás

• Fut, nem toboroz

  Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

  NCT03104842· 2. fázis· Forrás

• Lezárult

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· 3. fázis· Forrás

• Lezárult

  HD21

  NCT02661503· 3. fázis· Forrás

• Lezárult

  Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

  NCT02486718· 3. fázis· Forrás

• Lezárult

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· 3. fázis· Forrás